Gland Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	64,307	56,165	56,647	36,246	44,007
Revenue Growth (YoY)	14.50%	-0.85%	56.28%	-17.64%	27.08%
Cost of Revenue	24,458	24,621	25,539	18,595	22,494
Gross Profit	39,849	31,544	31,108	17,651	21,513
Selling, General & Admin	16,288	14,120	12,668	4,047	3,397
Other Operating Expenses	7,265	4,878	5,065	3,271	3,009
Operating Expenses	27,790	22,822	21,393	8,807	7,513
Operating Income	12,059	8,721	9,715	8,844	14,000
Interest Expense	-332.79	-373.99	-217.9	-62.87	-34.02
Interest & Investment Income	-	2,043	1,506	1,794	1,386
Currency Exchange Gain (Loss)	-	2.63	106.05	571.45	792.05
Other Non Operating Income (Expenses)	3,163	203.03	179.46	-1.07	-2.85
EBT Excluding Unusual Items	14,889	10,596	11,288	11,146	16,142
Gain (Loss) on Sale of Investments	-	12.27	3.48	28.48	44.89
Gain (Loss) on Sale of Assets	-	0.32	2.49	-0.81	-1.78
Asset Writedown	-	18.24	-	-63.32	-
Other Unusual Items	-243.46	-	-	-564.61	-
Pretax Income	14,646	10,627	11,325	10,546	16,186
Income Tax Expense	4,373	3,641	3,601	2,735	4,069
Net Income	10,273	6,985	7,725	7,810	12,117
Net Income to Common	10,273	6,985	7,725	7,810	12,117
Net Income Growth	47.07%	-9.57%	-1.10%	-35.54%	21.54%
Shares Outstanding (Basic)	165	165	165	165	164
Shares Outstanding (Diluted)	165	165	165	165	165
Shares Change (YoY)	0.13%	0.01%	0.03%	0.09%	3.96%
EPS (Basic)	62.35	42.40	46.90	47.44	73.81
EPS (Diluted)	62.28	42.40	46.89	47.43	73.64
EPS Growth	46.89%	-9.58%	-1.14%	-35.59%	16.91%
Free Cash Flow	5,406	5,302	6,069	1,430	2,794
Free Cash Flow Per Share	32.77	32.18	36.84	8.69	16.98
Dividend Per Share	20.000	18.000	20.000	-	-
Dividend Growth	11.11%	-10.00%	-	-	-
Gross Margin	61.97%	56.16%	54.92%	48.70%	48.88%
Operating Margin	18.75%	15.53%	17.15%	24.40%	31.81%
Profit Margin	15.97%	12.44%	13.64%	21.55%	27.53%
Free Cash Flow Margin	8.41%	9.44%	10.71%	3.95%	6.35%
EBITDA	16,295	12,314	12,968	10,310	15,102
EBITDA Margin	25.34%	21.93%	22.89%	28.44%	34.32%
D&A For EBITDA	4,237	3,593	3,253	1,466	1,101
EBIT	12,059	8,721	9,715	8,844	14,000
EBIT Margin	18.75%	15.53%	17.15%	24.40%	31.81%
Effective Tax Rate	29.86%	34.27%	31.79%	25.94%	25.14%
Revenue as Reported	67,470	58,301	58,350	38,651	46,246

Source: S&P Global Market Intelligence. Standard template. Financial Sources.